home / stock / ruby / ruby news

RUBY News and Press, Rubius Therapeutics Inc. From 05/28/19

Stock Information
Company Name: Rubius Therapeutics Inc.
Stock Symbol: RUBY
Market: OTC
Website: rubiustx.com
Menu
RUBY RUBY Quote RUBY Short RUBY News RUBY Articles RUBY Message Board
Get RUBY Alerts

News, Short Squeeze, Breakout and More Instantly...
RUBY - Rubius Therapeutics to Present at Jefferies 2019 Healthcare Conference

CAMBRIDGE, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY),  a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, announced today that Pablo J. Cagnon...
RUBY - Rubius Therapeutics misses by $0.01

Rubius Therapeutics (NASDAQ: RUBY ): Q1 GAAP EPS of -$0.42 misses by $0.01 . More news on: Rubius Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

RUBY - Rubius Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress

Enrollment for Phase 1b Trial of RTX-134 for Phenylketonuria on Track for Second Quarter 2019; Initial Clinical Data Anticipated in Second Half 2019 Company Announces Transition of President Torben Straight Nissen, Ph.D. CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- Rubius The...

RUBY - Notable earnings before Wednesday's open

BABA , ERJ , M , PLCE , PPDF , RUBY , TSEM , TSG For Seeking Alpha's full earnings season calendar,  click here . More news on: Alibaba Group Holding Limited, Embraer S.A., Macy's, Inc., Earnings news and commentary,

RUBY - Rubius Therapeutics to Announce First Quarter 2019 Financial Results

CAMBRIDGE, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced plans to report first quarter ...

RUBY - Biotech Stocks Hitting the Public Market This Year: Best Ones to Watch

Last year was a record year for biotech stocks, with an impressive number of companies going public and raising a significant amount of money in the space. In fact, in 2018 there were 80 biotech IPOs that raised a record total of $8.65 billion in gross proceeds. This trend is continuing...

RUBY - Rubius Therapeutics (RUBY) Presents At Jefferies 6th Annual IO Cell Therapy Summit - Slideshow

The following slide deck was published by Rubius Therapeutics, Inc. in conjunction with this Read more ...

RUBY - Rubius Therapeutics to Participate in Jefferies 6th Annual IO Cell Therapy Summit

CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY),  a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, announced today that Torben Straig...

RUBY - Rubius Therapeutics Announces Extensive Preclinical Data for Three Red Cell Therapeutic Oncology Programs at the 2019 American Association for Cancer Research Annual Meeting

CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced that the company present...

RUBY - Rubius Therapeutics beats by $0.07

Rubius Therapeutics (NASDAQ: RUBY ): Q4 GAAP EPS of -$0.35  beats by $0.07 . More news on: Rubius Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Previous 10 Next 10